Intensive insulin therapy combined with metformin is associated with reduction in both glucose variability and nocturnal hypoglycaemia in patients with type 2 diabetes.

Yifei ZhangZhiyun ZhaoShujie WangWei ZhuYiran JiangShouyue SunChen ChenKai WangLiangshan MuJinyi CaoYingxia ZhouWeiqiong GuJie HongWeiqing WangGuang Ning

Published in: Diabetes/metabolism research and reviews (2017)

Metformin added to initial CSII or MDI therapy is associated with a reduction in both glucose fluctuation and nocturnal hypoglycaemic risk in patients with type 2 diabetes.

Keyphrases

type diabetes
blood pressure
obstructive sleep apnea
blood glucose
sleep quality
sleep apnea
stem cells
glycemic control
metabolic syndrome
depressive symptoms
skeletal muscle
insulin resistance